<DOC>
	<DOCNO>NCT00739206</DOCNO>
	<brief_summary>The objective study assess efficacy safety SAR97276A severe malaria pediatric patient . Before treat pediatric patient severe malaria , efficacy safety SAR97276A first test adult patient , pediatric patient , uncomplicated malaria . The safety concentration SAR97276A blood plasma assess adult pediatric patient .</brief_summary>
	<brief_title>Study SAR97276A Treatment Uncomplicated Severe Malaria Adults Children .</brief_title>
	<detailed_description>The treatment administer intramuscular intravenous route depend cohort . The treatment administer single dose 3-day repeat dose . The patient hospitalize 3 day follow 28 day follow study treatment .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Adult patient uncomplicated malaria enrol cohort 1 Pediatric patient uncomplicated malaria enrol cohort 2 Pediatric patient severe malaria enrol cohort 3 Plasmodium falciparum malaria confirm blood smear Fever within last 24 hour . Treatment antimalarial agent within 72h screen Severe concomitant disease Pregnant breastfeed woman Women child bear potential protected effective method birth control The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>uncomplicated</keyword>
	<keyword>severe</keyword>
	<keyword>treatment</keyword>
	<keyword>Plasmodium Falciparum</keyword>
</DOC>